Acute Hepatitis A Viral Infection in People With HIV With Previously Documented Hepatitis A Immunity or Appropriate Vaccination: A Case Series

Stephanie E. McLaughlin,1,2 Jason D. Simmons,2 Hilary Armstrong,2 Elysia Gonzales,2 Robert M. Rakita,1 Jeffrey S. Duchin,1,2 and Rena C. Patel1,3

1Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle, Washington, USA; 2Public Health – Seattle and King County, Seattle, Washington, USA; and 3Department of Global Health, University of Washington, Seattle, Washington, USA

We describe 4 people with HIV (PWH) who acquired acute hepatitis A (HAV) infection during recent King County, Washington, outbreaks despite documented immunity and/or vaccination. HAV revaccination may be needed in PWH with risk factors for HAV infection regardless of preexisting immunity.

Keywords. hepatitis; HAV; HIV; vaccination.

Hepatitis A (HAV) infection is transmitted fecal-orally through either direct person-to-person contact or consumption of contaminated food or water [1]. HAV has historically caused self-limited symptoms and has resulted in few hospitalizations [1, 2]. However, more recently, hospitalizations have risen as numerous outbreaks have been noted throughout the United States [1, 3]. People with HIV (PWH) are at risk for adverse HAV outcomes, including more profound liver function dysfunction and prolonged viremia and viral shedding [4, 5]. They may also mount a less robust or durable vaccination response than their HIV-negative counterparts [6–8]. While 85% of vaccinated PWH had durable HAV seropositivity postvaccination in a study by Crum-Cianflone et al., the longevity of this HAV antibody response varied markedly from 6 to 10 years. Suppressed HIV viral load and higher CD4 cell counts at vaccination were associated with increased longevity of antibody titers [9].

The newest Centers for Disease Control and Prevention (CDC) guidance recommends vaccinating all PWH age >1 year for HAV [6]. The guidelines also suggest considering booster vaccination of PWH who do not demonstrate an adequate immune response or who later demonstrate an improvement in immune status [6]. However, it remains unclear if PWH who have adequate anti-HAV antibody titers and/or who were vaccinated with high CD4 cell counts should receive HAV booster vaccination, particularly during local HAV outbreaks [6, 10].

Since January 1, 2019, King County has identified 2 separate HAV outbreaks spreading mainly via person-to-person transmission: (1) a small outbreak primarily among men who have sex with men (MSM; November 2018–March 2019) and (2) a large outbreak beginning in April 2019, primarily among persons experiencing homelessness (PEH) or persons who use drugs (PWUD). In the 2 years of these outbreaks, there have been a total of 194 cases of HAV—compared with a previous 10-year range of 5 to 16 cases per year—including 119 (61.3%) hospitalizations and 2 (1.0%) deaths. Of these 194 cases, 68% were male, the median age (range) was 42 (9–78) years, 60.3% occurred among PEH and/or PWUD, and 8.2% occurred among MSM [11]. Beyond King County, Washington state also declared a statewide HAV outbreak among PEH and PWUD in July 2019. Nationally, 35 states have reported similar outbreaks since 2016 [3].

During these local King County outbreaks, we provided clinical care for 4 PWH who developed acute HAV infection despite documented prior immunity or history of vaccination. To better describe any shared risk factors and highlight the limitations of current [re]vaccination guidelines, we present a detailed case series of these 4 individuals.

METHODS

We identified patients with acute HAV infection during outbreak surveillance within the above noted outbreaks. Coauthors on this report initiated a discussion with local public health collaborators when some coauthors identified 2 of these cases through direct patient care at the county hospital. We gathered data from surveillance records, case report forms, and medical records via existing public health and electronic medical records data systems. The University of Washington Human Subjects Division (Institutional Review Board) considered this reporting exempt from human subjects research.

RESULTS

We identified 4 PWH who acquired HAV infection between January 2019 and June 2020 despite having no known prior HAV infection and reporting a remote HAV vaccination history (Patients A–C) and/or documented past immunity (via qualitative HAV immunoglobulin G [IgG] positivity years after vaccination; Patient D). All 4 required hospitalization due to
their HAV infection. Details of patient characteristics and their courses are listed in Table 1.

Patient A was a 65-year-old man with chronic kidney disease and chronic heart failure who presented with 1 week of increasing fatigue and myalgias. At the time of acute HAV infection, he denied drug use, was consistently engaged in care and stable on antiretrovirals (ARVs), and was housed in a private apartment.

Patient B was a 38-year-old man who presented with 2 weeks of fevers, severe myalgias, anorexia, and diarrhea. He was also consistently engaged in HIV care and adherent to ARVs. He was stably housed in a private apartment and reported a recent history of inhaled methamphetamine.

Patient C was a 48-year-old man who presented with 3 weeks of progressive abdominal pain, anorexia, and jaundice. Patient C had less consistent antiretroviral adherence than Patients A or B and had recently discontinued ARVs in the setting of gastrointestinal complaints. Patient C had previously experienced homelessness, but at the time of this illness he had supportive housing. He also reported recent inhaled methamphetamine use.

Patient D was a 55-year-old transgender woman, male sex at birth, who presented with 10 days of fatigue, headache, fevers, and dark urine. She was also consistently engaged in HIV care and adherent to ARVs. She also reported housing in a private apartment and denied drug use.

Patients A–D all indicated condomless sex with a new male partner during their exposure period. All patients' liver function and subjective symptoms improved quickly with supportive care. They were discharged to home and returned to their baseline health status.

DISCUSSION

All 4 PWH presented here acquired acute HAV requiring hospitalization despite documented immune response after vaccination and/or prior documentation of HAV vaccination at CD4 ≥200 cells/mL. Several factors may account for HAV infection despite presumed immunity. First, we know that protective immunity may wane over time and lead to disease acquisition and that immunosuppressed states, such as HIV, may predispose individuals to less durable immunity [4, 7, 10, 12]. Vaccination at a CD4 count >200 is thought to predict long-lasting immunity in PWH [10]. Despite that, the patients in our case series were either vaccinated at a CD4 count >200 (Patient D) or had well-controlled HIV with long-standing undetectable HIV viral loads at the time of HAV vaccination (Patients A–C). Therefore, it is unlikely that secondary failures correlate with profound immune suppression at the time of vaccination in these patients. Accordingly, the reliance on CD4 count alone as an indicator of who will benefit from an HAV booster vaccination is insufficient.

Second, a past or current positive HAV IgG titer may be an unreliable correlate of protection from acute HAV infection in PWH. Neutralizing anti-HAV IgG titers, which are thought to be associated with lifelong protection [13], are significantly lower after inactivated HAV vaccination as compared with natural infection [14]. Total HAV IgG titers are correlated with neutralizing antibody titers [14] where a level of >10 mIU/mL is considered a surrogate correlate of protection in vaccine trials [15]. However, a minimum anti-HAV IgG level that confers protection in real-world situations has not been established. Three patients in our series (A–C) had positive HAV IgG titers both at the time of acute HAV infection and 3–8 years prior, which is consistent with their prior vaccination, although, admittedly, acute infection may have boosted HAV IgG titers. Further study is required to define the mechanisms of these secondary failures and may inform whether the traditional surrogate markers of immunity (ie, ≥10 mIU/mL anti-HAV IgG) should be modified for PWH. Possible mechanisms of these “breakthrough” infections could include a large inoculum related to unprotected anal intercourse, particularly with oral–anal sex, or viral escape phenomenon overcoming any existing immunity. The latter possibility may be less likely given the viral fitness costs measured after mutations in viral capsid-neutralizing epitopes [16] but has been described in prior outbreaks associated with transmission among MSM [17]. Third, self-reported, and even well-documented, complete HAV vaccination may not be evidence of sufficient protection during an outbreak. A related case series detailed 6 male, previously HAV-vaccinated PWH who acquired acute HAV during a 2017–2018 Tennessee outbreak. In this series, over half of those infected had a documented partial or complete HAV vaccination series [18]. The Tennessee report, like ours, substantiates the concern that neither prior vaccination nor positive HAV IgG titers postvaccination can confidently predict protection from HAV infection in PWH during an outbreak.

Given the limitations of using CD4 monitoring, HAV IgG titers, and vaccination history to predict protection from acute HAV in PWH, we suggest that HAV booster vaccination be considered, especially during a local outbreak, based on risk factors for HAV acquisition irrespective of documented prior vaccination or immunity. The risk of HAV infection is higher in MSM [1]; as such, it is possible that anal intercourse, particularly anal–oral sex, delivers a larger HAV inoculum or at least increases rates of fecal–oral transmission as compared with other exposures. In our series, Patients A–C were MSM, and Patient D identified as a transgender woman (male at birth) with similar sexual risk factors for HAV infection. Of note, a limitation of our report is the lack of risk factor analysis with comparator groups, such as persons within the local HAV outbreak not living with HIV. However, no foodborne transmission risk factors were identified in the patients reported in this series. These 4 cases serve as “proof of concept” that some form of prior immunity is not protective against acute HAV infection during local outbreaks among PWH. As such, we posit that

| 2 • OFID • BRIEF REPORT  |
Table 1. Sociodemographic and Clinical Characteristics of PWH who Contracted Acute HAV Infection Despite Previously Documented HAV Immunity or Immunization

|                          | Patient A | Patient B | Patient C | Patient D |
|--------------------------|-----------|-----------|-----------|-----------|
| **Age, y**               | 65        | 38        | 48        | 55        |
| **Gender (sex at birth if differs from gender)** | Male      | Male      | Male      | Transgender woman (male sex at birth) |
| **Sexual orientation**   | MSM       | MSM       | MSM       | MSM       |
| **Housing**              | Stable, apartment with long-term male partner | Stable, single apartment | Stable, supportive group housing | Stable, single apartment |
| **Illicit drug use**     | None      | Current inhaled methamphetamine use, never IDU | Current inhaled methamphetamine use, past IDU >1 y ago | None |
| **Occupation**           | Disabled  | Ride-share driver | Technician for a meal service company | Unemployed |
| **Year of HIV diagnosis (years between HIAV and HAV diagnosis)** | 8         | 14        | 6         | 28        |
| **CD4 cell count nadir HIV VL history** | Unknown nadir UD VL since 2012 | Unknown nadir UD VL since 2011 | Nadir 736 cells/mL in 2018 Intermittently UD VL | Unknown nadir UD VL (since unknown date) |
| **Antiretroviral medication (at time of HAV diagnosis)** | Abacavir, lamivudine, raltegravir | Tenofovir, emtricitabine, bictegravir | Tenofovir, emtricitabine, dolutegravir | Abacavir, lamivudine, dolutegravir |
| **HAV vaccination status (years before HAV diagnosis)** | Self-reported prior vaccination (unknown date) | Self-reported prior vaccination (unknown date) | None documented | 12, 6 (2-dose series 12 and 6 y prior) |
| **CD4 cell count at HAV vaccination, cells/mL** | Unknown | Unknown | Unknown | 333 |
| **HAV IgG positivity (years before HAV diagnosis)** | 8 | 3 | 3 | Not known |
| **CD4 cell count and HIV VL (within year before HAV diagnosis), cells/mL, copies/mL** | 379, UD | 803, UD | 800, 1636 | 1013, UD |
| **Likely source of acute HAV acquisition** | Condomless sex with new male partner 2–3 wk prior (not long-term partner) | Condomless sex with new male partner 2 wk prior | Condomless sex with new male partner 2–3 wk prior | Condomless receptive anal sex with new, consistent male partner for 2 mo prior |
| **LFT peak (AST/ALT, total bilirubin), units/L** | 2732/5049, 5.9 | 2493/5010, 6.7 | 1708/4531, 13.1 | 538/1090, 6.0 |
| **Radiologic findings** | Normal liver US (no doppler) | Liver US: slightly echogenic liver parenchyma is suggestive of diffuse hepatocellular disease (no doppler) | Liver US with doppler: subtle hepatic parenchymal edema, typical for acute hepatitis, no vascular anomalies, thrombosis, or biliary obstruction | None |
| **HCV**                  | HCV Ab and PCR neg | HCV Ab neg | HCV Ab neg | HCV Ab neg |
| **Other workup**         | HBV sAb pos HBV sAg neg HBV PCR neg | HBV sAb pos HBV sAg neg | HBV sAb pos HBV sAg neg | HBV sAg neg |
| **CMV**                  | PCR neg IgM and IgG neg | PCR neg | Not known | Not known |
| **HSV**                  | PCR neg Reactive IgG | PCR neg | Not known | Not known |
| **Autoimmune**           | ANA neg (8 y prior) | ANA neg | ANA neg, anti-smooth muscle Ab pos 1:80 | ANA neg (12 y prior) |
| **STI testing at admission** | Urine GC/CT NAATs neg | Syphilis neg | Syphilis neg Rectal and pharyngeal GC/CT NAATs neg | RPR pos (titer 1:32) Urine GC/CT NAATs neg |
| **HAV IgM at admission** (Ig level if known, g/L) | Posb | Posb (7.10) | Posb (10.8) | Posb |
| **HAV IgG at presentation** (Ig level if known, g/L) | Pos* (level unknown) | Pos* (3.9) | Pos* (3.8) | Not known |
| **HAV PCR (at admission)** | Pos | Pos | Pos | Pos |

Abbreviations: Ab, antibody; ANA, antinuclear antibody; CMV, cytomegalovirus; CT, chlamydia; GC, gonorrhea; HBV, hepatitis B virus; HCV, hepatitis C virus; HSV, herpes simplex virus; IDU, intravenous drug use; Ig, immunoglobulin; LFTs, liver function tests; MSM, men who have sex with men; NAAT, nucleic acid amplification test; PCR, polymerase chain reaction; RPR, rapid plasma regain; STI, sexually transmitted infection; TGNB, transgender and nonbinary; UD, undetectable; VL, viral load.

*Positive >1.21 (s/co).
**Positive >1.0 (s/co).
certain sexual behaviors historically associated with MSM, such as anal–penile sex or anal–oral sex, reported by PWH should prompt consideration of an HAV booster vaccination during a local outbreak.

HAV risk factors, such as homelessness (PEH), drug use (PWUD), and predisposing sexual behaviors, often coexist within individual patients and patient populations. A comprehensive social history, including a detailed history of drug use and specific sexual behaviors, will help clinicians identify PWH who may benefit from booster vaccination during an outbreak.

Single booster vaccination has been shown to generate sufficient immune response in PWH [6, 10, 12]. Nevertheless, future clinical guidelines should be informed by modeling and cost-effectiveness studies that evaluate both vaccine manufacturing and distribution costs as well as the high cost of HAV outbreak-associated hospital care [19]. Logistical considerations, such as supply or administration during the coronavirus disease 2019 pandemic, must also be accounted for in future public health policy regarding HAV booster vaccination.

Acknowledgments
Molecular typing of HAV isolates was completed by Sumathi Ramachandran, Yulin Lin, and Po-Yi Ho within the CDC Division of Viral Hepatitis Laboratory.

Financial support. Drs. Stephanie E. McLaughlin’s (NIAID T32 AI007140-43), Rena C. Patel’s (NIAID K23AI120855), and Jason D. Simmons’ (K08AI143926) efforts were supported by the National Institutes of Health.

Potential conflicts of interest. Stephanie E. McLaughlin: no conflict. Jason D. Simmons: no conflict. Hilary Armstrong: no conflict. Elysa Gonzales: no conflict. Robert M. Rakita: no conflict. Jeffrey S. Duchin MD: no conflict. Rena C. Patel: no conflict. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Patient consent. The University of Washington Human Subjects Division (Institutional Review Board) considered this reporting exempt from human subjects research; therefore, this study does not necessitate patient consent.

References
1. Hofmeister MG, Xing J, Foster MA, et al. Hepatitis A person-to-person outbreaks: epidemiology, morbidity burden, and factors associated with hospitalization—multiple states, 2016-2019. J Infect Dis 2021; 223:426–34.
2. Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122:226–33.
3. Centers for Disease Control and Prevention. Widespread person-to-person outbreaks of hepatitis A across the United States. Available at: https://www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.htm. Accessed 3 March 2021.
4. Ida S, Tachikawa N, Nakajima A, et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002; 34:379–85.
5. Lee YL, Chen GJ, Chen NY, et al; Taiwan HIV Study Group. Less severe but prolonged course of acute hepatitis A in human immunodeficiency virus (HIV)-infected patients compared with HIV-uninfected patients during an outbreak: a multicenter observational study. Clin Infect Dis 2018; 67:1595–602.
6. Nelson NF, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69:1–38.
7. Tseng YT, Chang SY, Liu WC, et al. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology 2013; 57:1734–41.
8. Huang SH, Huang CH, Wang NC, et al; Taiwan HIV Study Group. Early seroreversion after 2 doses of hepatitis A vaccination in human immunodeficiency virus-positive patients: incidence and associated factors. Hepatology 2019; 70:465–75.
9. Crum-Cianflone NF, Wilkins K, Lee AW, et al; Infectious Disease Clinical Research Program HIV Working Group. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011; 203:1815–23.
10. Lin KY, Chen GJ, Lee YL, et al. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: a review. World J Gastroenterol 2017; 23:3589–606.
11. King County.gov. Hepatitis A in King County, 2019-2020. Available at: https://www.kingcounty.gov/depts/health/communicable-diseases/disease-control/hepatitis-A/dashboard.aspx. Accessed 2 February 2021.
12. Chen GJ, Sun HY, Lin KY, et al. Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination. Liver Int 2018; 38:1198–205.
13. Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983; 148:1033–9.
14. Lemon SM, Murphy PC, Provost PJ, et al. Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. J Infect Dis 1997; 176:9–19.
15. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055–65.
16. Lemon SM, Binn LN, Marchwicki R, et al. In vivo replication and reversion to wild type of a neutralization-resistant antigenic variant of hepatitis A virus. J Infect Dis 1990; 161:7–13.
17. Pérez-Sautu U, Costafreda MI, Caply I, et al. Hepatitis A virus vaccine escape variants and potential new serotype emergence. Emerg Infect Dis 2011; 17:734–7.
18. Brennan J, Moore K, Sizemore L, et al. Notes from the field: acute hepatitis A virus infection among previously vaccinated persons with HIV infection — Tennessee, 2018. Morbidity Mortal Wky Rep 2019; 68:328–9.
19. Batdorf SJ, Hofmeister MG, Surtees TC, et al. Estimated Medicaid costs associated with hepatitis A during an outbreak — West Virginia, 2018–2019. Mmwr Morbidity Mortal Wky Rep 2021; 70:269–72.